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ABSTRACT:
The aberrant expressions of casein kinase 2 (CK2) was found in prostate cancer 
patient and cell lines, but little is known of the detailed mechanisms implicated in 
prostate tumorigenesis. In this study, we report that both CK2 activity and CK2-
mediated NCoR phosphorylation are significantly elevated in the androgen-independent 
prostate cancer cell line DU145 and PC-3 compared with RWPE1 and LNCaP cells. 
Increased phosphorylation inversely correlates with the mRNA level of the NCoR-
regulated gene, interferon-γ-inducible protein 10 (IP-10). CK2 inhibition abrogated 
NCoR phosphorylation, IP-10 transcriptional repression, and the invasion activity of 
PC-3 cells. Inhibition of the CK2-NCoR network significantly reduced in vivo PC-3 cell 
tumorigenicity, likely due to transcriptional derepression of IP-10. Clinicopathological 
analyses revealed that increased CK2-mediated NCoR phosphorylation significantly 
correlates with poor survival among prostate cancer patients. These findings elucidate 
a CK2-modulated oncogenic cascade in prostate tumorigenesis. 
INTRODUCTION
Casein kinase 2 (CK2) is a multifunctional protein 
kinase with a wide range of protein substrates, many 
of which are critically involved in the processes of cell 
cycle control, cellular differentiation, proliferation, 
and metabolism [1]. Moreover, CK2 can exert anti-
apoptotic effects through various mechanisms [2-4]. 
Thus, dysregulation of CK2 in tumor cells may influence 
apoptotic activity and enhance cell survival [5, 6]. 
Overexpression of CK2α leads to increased c-myc 
expression in T cell lymphoma [7], NFκB activation in 
NIH3T3 cells [8], and protects PC-3 cells from etoposide-
induced apoptosis [9]. Overexpression of CK2β in 3T3-
L1 fibroblasts results in an increased growth rate [10]. In 
transgenic mice, CK2α overexpression cooperates with 
c-myc or p53 loss (or mutation) at the lpr locus to promote 
tumorigenesis [11]. Transgenic expression of CK2α under 
the MMTV promoter resulted in late onset squamous 
adenocarcinomas with increased c-myc and β-catenin 
expression [12]. Moreover, CK2 participates in the control 
of Snail1, a major factor for epithelial-mesenchymal 
transition, by stabilizing and positively regulating Snail1 
repressive function and its interaction with the mSin3A 
corepressor [13]. Therefore, CK2 is recently highlighted 
as promising target for cancer therapies [5, 14, 15]. 
Recent studies have demonstrated that CK2 
expression and activity are highly elevated in multiple 
tumors and tumor cell lines [9, 16]. For example, two 
esophageal cancer cell lines, TE2 and HCE4, displayed 
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opposing CK2 activities, but similar CK2 expression 
levels [17, 18]. This differential pattern of CK activity 
correlated with the invasive growth of esophageal cancer 
cells [18]. In addition, the androgen-independent prostate 
cancer cell line PC-3 also displays relatively elevated CK2 
activity compared to LNCaP prostate cells [19, 20]. In 
accordance with these observations, targeting CK2α with 
antisense RNA or inhibitors induces tumor shrinkage in 
a human prostate cancer xenograft model, suggesting the 
importance of CK2 in prostate tumorigenesis [3, 21, 22]. 
Although the importance of CK2 in tumor cell survival 
and growth is clear, the molecular mechanism by which 
CK2 is involved in prostate tumorigenesis has not been 
extensively investigated.
Nuclear receptor corepressor (NCoR) forms 
corepressor complexes with histone deacetylase 3 
(HDAC3) to induce changes in local chromatin structure 
and thereby cause transcriptional repression [23-25]. 
NCoR interacts with antagonist-bound androgen receptor 
(AR) to repress its activity, which is believed to be 
the basic principle for the current widespread use of 
hormone therapy for prostate cancer [26, 27]. During the 
progression to castration-resistant prostate cancer (CRPC), 
coactivators such as SRC-1 and TIF-2 greatly contribute to 
the growth of androgen-independent prostate cancer cells 
by reactivation of AR by coactivators which are highly 
overexpressed in recurrent prostate cancer compared 
with benign prostatic hyperplasia or androgen-dependent 
prostate cancer [28]. However, the role of AR corepressors 
during androgen-independent prostate cancer progression 
is still unclear. In this regard, we recently proposed an 
oncogenic cascade where both CK2 and NCoR selectively 
repress the transcription of a sub-set of target genes 
including the anti-tumorigenic gene interferon-γ-inducible 
protein 10 (IP-10), to promote oncogenic signaling in 
human cancer cells [18]. Although we suggested the 
molecular basis for CK2-NCoR cascade for tumorigenic 
growth of cancer cells in vitro, the clinical implications 
of this cascade in human cancer development is currently 
unknown. 
In this study, we demonstrate the clinical relevance 
of the CK2-NCoR axis in prostate cancer development 
and provide a mechanism related to the invasive growth 
of malignant prostate cancer cell, PC-3. Furthermore, we 
show that blocking the CK2-NCoR network suppresses 
the in vivo tumorigenicity of prostate cancer cells via 
derepression of IP-10 mRNA, which may provide a potent 
therapeutic strategy for the treatment of prostate tumor 
Figure 1: Constitutive activation of CK2 and NCoRS2436 phosphorylation in PC-3 cells. (A) In vitro kinase assays were 
performed by incubating GST-NCoR-15/16 protein and immunoprecipitated CK2 enzyme obtained from indicated prostate cancer cells. 
NCoR phosphorylation levels were analyzed by autoradiography and scintillation counts (left & middle panel). Error bars indicate SD 
(n=3). Cell lysates from prostate cancer cells were analyzed by Western blotting (right panel). (B) For the Duolink in situ PLA analysis, 
indicated cells were seeded on coverslips and treated with the siNCoR in the presence of DMSO or TBB (50 µm). The pre-metabolized 
cells were incubated with the indicated antibodies and treated with PLA probes (PLUS and MINUS). The positive signal was analyzed 
using confocal microscopy. (C) Expression of NCoRS2436 phosphorylation was examined using immunohistochemical staining in samples 
from prostate cancer patients. Representative NCoRS2436 phosphorylation levels are shown in two normal and tumor sections. The nuclei 
were counterstained with hematoxylin. (D) Expression levels of indicated genes from prostate cancer cells were analyzed by real-time PCR. 
Error bars indicate SD (n=3).
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progression.
RESULTS
CK2-mediated NCoR phosphorylation is elevated in 
PC-3 cells 
Recent studies demonstrated that NCoR expression 
is frequently elevated in malignant prostate cells compared 
with non-malignant cells [29, 30]. Furthermore, aberrant 
expression of CK2 has been reported in prostate cancers 
[19, 20, 31]. Therefore, we first assessed the relative 
activity of CK2 in among various prostate cell lines, 
including a non-transformed prostate epithelial cell line 
(RWPE1), an androgen-dependent prostate cancer cell line 
(LNCaP), and an androgen-independent prostate cancer 
cell line (PC-3). In vitro kinase assays revealed that CK2 
activities in PC-3 cells are significantly higher than in both 
RWPE1 and LNCaP cells (Fig. 1A, left panel); however, 
CK2α inhibitor TBB treatment of PC-3 cells decreased 
CK2 activity (Fig. 1A, middle panel). Next, we examined 
the relative level of CK2-mediated NCoR phosphorylation 
among these cell lines with a phospho-specific NCoR 
antibody that specifically recognizes phosphorylated Ser-
2436 of NCoR as described previously [18]. Intriguingly, 
significant levels of both NCoR and phosphor-NCoRS2436 
were observed in PC-3 cells compared with LNCaP 
and RWPE1 (Fig. 1A, right panel). This correlates with 
the results from an in vitro kinase assay, suggesting 
constitutive activation of the CK2-NCoR cascade in PC-3 
cells (Fig. 1A). We also observed no significant difference 
in CK2 and HDAC3 levels among these cells (Fig. 1A). 
It is also noteworthy that the levels of NCoR and NCoR 
phosphorylation is elevated in LNCaP-derivative C4-2B 
cells compared with LNCaP cells, although to a less than 
both DU145 and PC-3 cells, implying the plausible role of 
Figure 2: The activated CK2-NCoR network promotes invasion activity of PC-3 cells. (A) PC-3 cells were treated with 
TBB (50 µM, 6 hr) or the indicated siRNAs and cDNA was prepared for real-time PCR. Error bars indicate SD (n=3).  Cell lysates were 
analyzed by Western blotting. (B) PC-3 cells were treated with CK2 inhibitors (TBB, emodin) or transfected with siNCoR. cDNA was 
prepared for real-time PCR analysis. Error bars indicate SD (n=3). (C) Invasive growth of prostate cancer cells was analyzed by counting 
cells that migrated through the extracellular matrix layer of Biocoat Matrigel invasion chambers. Error bars indicate SD (n=3) (left panel). 
PC-3 cells were transfected with the indicated siRNAs and expression plasmids in the presence or absence of TBB before application to 
the upper chamber. Error bars indicate SD (n=3) (right panel). (D) PC-3 cells were transfected with the indicated siRNAs or treated with 
TBB. Invasive growth was analyzed by counting cells that migrated through the extracellular matrix layer of Biocoat Matrigel invasion 
chambers. Error bars indicate SD (n=3) (left panel). The level of IP-10 mRNA was determined by real-time PCR. Error bars indicate SD 
(n=3). (right panel).
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CK2-NCoR cascade in hormone independency of prostate 
cancer cells (Supplementary Figure 1). Importantly, 
DuoLink in situ proximity ligation assay (PLA) analysis 
verified elevated levels of NCoRS2436 phosphorylation 
in PC-3 cells (Fig. 1B). Consistently, TBB efficiently 
blocked NCoR S2436 phosphorylation in PC-3 cells, further 
confirming elevated CK2-NCoR signaling in PC-3 
cells. To corroborate this finding, we have examined 
whether CK2-mediated NCoR phosphorylation is 
elevated in prostate cancer patients. As shown in Fig. 
1C, immunohistochemical analyses demonstrate elevated 
levels of phosphor-NCoRS2436 in tumor regions compared 
with adjacent non-neoplastic prostate tissues, suggesting 
a possible role for the CK2-NCoR signaling cascade in 
prostate tumorigenesis. 
The IP-10/CXCL10 gene was identified as a CK2 
and NCoR network-regulated gene [18]. Therefore, we 
assessed the mRNA level of IP-10 in prostate cancer cells. 
Real-time PCR analyses demonstrated reduced levels 
of IP-10 mRNA in PC-3 cells compared with RWPE1 
and LNCaP cells, which inversely correlates with CK2-
mediated NCoR phosphorylation (Fig. 1D). This data 
supports the hypothesis that CK2 phosphorylates NCoR to 
repress the transcription of IP-10 in PC-3 cell. In addition, 
ONCOMINE database analysis indicated decreased 
mRNA levels of IP-10 in prostate cancer patients 
compared with normal patients or patients with other 
cancer types (Supplementary Figure 2). Together, these 
data suggest that the CK2-NCoR oncogenic cascade, at 
least in part, is involved in prostate cancer tumorigenesis 
via transcriptional repression of IP-10.
The CK2-NCoR network promotes invasive growth 
of PC-3 Cells
To elucidate the relationship between CK2-NCoR 
signaling and prostate tumorigenesis, we first investigated 
whether the depletion of NCoR selectively represses IP-10 
transcription in PC-3 cells. As shown in Fig. 2A, inhibition 
or depletion of CK2 derepressed the transcription of both 
E-cadherin and IP-10. However, NCoR knockdown 
selectively derepressed IP-10, confirming that the CK2-
NCoR network selectively represses IP-10 transcription 
in PC-3 cells. It is noteworthy that TBB treatment 
dramatically reduced the elevated levels of both NCoR 
and phosphor-NCoRS2436 in PC-3 cell (Fig. 2A), again 
emphasizing the role of CK2 on NCoR stabilization. 
In addition, treating cells with another CK2α inhibitor, 
Emodin, in combination with siNCoR, also verified the 
selective repression of IP-10 transcription by the CK2-
NCoR network (Fig. 2B).
Consistent with increased CK2 activity and 
NCoR phosphorylation, we also observed increased 
invasion activity in PC-3 cells compared with RWPE1 
and LNCaP cells (Fig. 2C, left panel). This increased 
Figure 3: CK2 activity is required for the recruitment of the NCoR-HDAC3 corepressor complex to AP-1 site of the 
IP-10 promoter in PC-3 cells. (A) A diagram of the IP-10 promoter showing the position of the AP-1 site and the primers used for 
real-time PCR analyses in ChIP assays. ChIP assays were performed with the indicated antibodies. The precipitated samples were analyzed 
by real-time PCR, and results are given as the percentage of input (mean ± SD of three independent experiments). Error bars indicate SD 
of three independent sets. * p<0.01 vs. LNCaP; ** p<0.001 vs. LNCaP (B) PC-3 cells were treated with or without TBB and ChIP/reChIP 
assays were performed with the indicated antibodies. Error bars indicate SD of three independent sets. * p<0.05; ** p<0.01.
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invasion activity of PC-3 cells seemed to be dependent 
on CK2 activity, since either siCK2 or TBB treatment 
significantly impaired the invasion activity of PC-3 
cells (Fig. 2C). Importantly, combinatorial treatment of 
siCK2 or siNCoR with overexpression of IP-10 further 
suppressed the invasive growth of PC-3 cells, suggesting 
the functional significance of CK2-NCoR-IP-10 signaling 
in tumorigenic growth of PC-3 cells (Fig. 2C, right panel 
and Supplementary Figure 3A).
Since the repressive function of the NCoR 
corepressor complex depends on HDAC3[25], we next 
assessed the effect of knocking down HDAC3 on the 
invasive growth of PC-3 cells. As shown in Fig. 2D (left 
panel), depletion of NCoR synergistically suppressed 
the invasive growth of PC-3 cells when treated with 
TBB. Combinatorial treatment of TBB with siHDAC3 
also displayed a synergistic effect on invasive growth 
of PC-3 cells, indicating a functional engagement of the 
NCoR-HDAC3 corepressor complex in invasive growth 
of PC-3 cells (Supplementary Figure 3B). As expected, 
we also observed enhanced derepression of IP-10 upon 
combinatorial treatment of TBB and siHDAC3 (Fig. 2D, 
right panel).
Decreased expression of IP-10 in PC-3 cells is 
associated with enhanced recruitment of the NCoR-
HDAC3 corepressor complex to the AP-1 site of IP-
10 gene
Because we observed constitutively elevated levels 
of CK2 activity in PC-3 cells and a corresponding decrease 
in IP-10 transcription, we investigated the relative 
occupancy of the NCoR-HDAC3 corepressor complex 
in the IP-10 gene promoter region in prostate cancer 
cells. We previously identified a c-Jun-binding AP-1 site 
in the IP-10 gene promoter at position -2,044 to -2,050 
(relative to the transcription start site) [18]. Chromatin 
immunoprecipitation (ChIP) experiments indicated the 
recruitment of NCoR and HDAC3 to the IP-10 promoter 
was increased in PC-3 cells compared with RWPE1 and 
LNCaP cells (Fig. 3A). In contrast, increased occupancy 
of the c-Fos and p300 promoters was observed in 
RWPE1 and LNCaP cells. These data suggest differential 
recruitment of the NCoR-HDAC3 corepressor complex 
to the AP-1 site of the IP-10 gene promoter determines 
the level of IP-10 mRNA, which correlates with invasion 
Figure 4: Effect of CK2-NCoR axis inhibition on in vivo tumorigenecity of PC-3 cells. (A) Stable PC-3 cells that express 
shNCoR were generated as described in the Materials and Methods. The cell lysates were subsequently immunoblotted with the indicated 
antibodies. (B-C) Stably transfected PC-3 cells (1.5 x 106 cells) were injected subcutaneously into the right flank of nude mice. Mice were 
sacrificed 9 weeks post injection. Tumor volume (B) and weight (C) were measured for 9 weeks. Values give are the mean ±SD for eight 
mice from a representative experiment. (D) Mice were sacrificed and tumor tissues were collected, processed, and subjected to real-time 
PCR. Error bars indicate SD (n=3).
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activity of prostate cancer cells. 
Next, we examined whether CK2 activity  is 
required for increased NCoR-HDAC3 corepressor 
complex binding to the AP-1 site of the IP-10 promoter. 
As shown in Fig. 3B, ChIP and ReChIP analyses 
demonstrated that both NCoR and HDAC3 associate 
with c-Jun in the AP-1 site to repress IP-10 transcription, 
whereas c-Fos is dissociated from c-Jun. Importantly, TBB 
treatment induced NCoR corepressor complex dissociation 
from the AP-1 site as well as increased formation of the 
c-Jun/c-Fos activating complex. These data suggest that 
enhanced CK2 activity in PC-3 cells stabilizes the NCoR 
protein and subsequently increases the formation of c-Jun-
NCoR-HDAC3 corepressor complex in the AP-1 site to 
constitutively repress IP-10 transcription.
CK2-NCoR pathway inhibition suppresses in vivo 
tumorigenesis of PC-3 cells via repression of IP-10 
Given the critical role of CK2-NCoR signaling in 
the in vitro tumorigenicity of PC-3 cells, we next examined 
whether inhibition of CK2 and NCoR inhibits their in vivo 
tumorigenecity. To this end, we generated several stable 
PC-3 cell lines with NCoR knocked down using lentiviral 
shRNAs and selected the cell line with the most efficient 
lentiviral shRNA against NCoR (Fig. 4A). As shown in 
Fig. 4B, a xenograft assay using subcutaneous injection 
of PC-3 cells into nude mice demonstrated that TBB 
treatment or stable knockdown of NCoR significantly 
reduced tumor volume and size compared with control 
(Fig. 4C). We next examined whether the inhibition of 
Figure 5: Inverse relationship between IP-10 and NCoR phosphorylation during prostate cancer development. (A) 
Immunohistochemical staining of tissue sections was performed using phospho-NCoR and IP-10 antibodies at a 1:100 dilution. (B) 
Immunohistochemical staining of tissue sections was scored semi-quantitatively. The semi-quantitative analysis of immunohistochemical 
staining was calculated by: expression score = percentage of staining (0-3) + intensity score (0–3) among 55 patients with prostate cancer 
tissue. (C) Inverse relationship of phospho-NCoR with IP-10 expression between high-Gleason score (≥8) prostate cancer patients. (D) The 
survival rate of high-Gleason score (≥8) prostate cancer patients was significantly lower than that of low-Gleason score (≤7) prostate cancer 
patients according to Kaplan–Meier survival curve analyses. (E) Kaplan–Meier curves (upper panel) and Cox proportional hazard model 
analyses (lower panel) estimate the survival rate according to the phospho-NCoR level in the cohort. The Cox proportional hazard model 
analysis was performed after adjustments for age and Gleason score (continuous variable). 
Oncotarget 2013; 4: 972-983978www.impactjournals.com/oncotarget
tumorigenecity is attributed to derepression of IP-10 and 
blocking the CK2-NCoR network. As shown in Fig. 4D, 
real-time PCR analyses using mrna from tumor samples 
demonstrate the level of IP-10 mrna is inversely associated 
with PC-3 cell in vivo tumorigenicity. This result suggests 
that IP-10 expression correlates with tumor growth but 
may not necessarily be causative. Collectively, these data 
indicate that the CK2-NCoR signaling network suppresses 
in vivo tumorigenecity of PC-3 cells.
Inverse relationship between CK2-mediated NCoR 
phosphorylation and IP-10 expression during 
prostate cancer development
To further explore the clinical relevance of CK2-
NCoR signaling and prostate cancer development, NCoR 
phosphorylation and IP-10 expression were evaluated by 
immunohistochemistry using tissue microarrays. Sixty two 
tissue samples from prostate cancer patients with diverse 
clinical stages were collected and semi-quantitative 
immunohistochemical staining using antibodies against 
NCoR Ser (P)-2436 and IP-10 was performed (Fig. 
5A). From the original cohort of patients, 56 prostate 
carcinomas were available for analysis because of loss 
of some tissue cores during processing of the tissue 
microarrays. The intensity of immunohistochemical 
staining was indicated by an expression score, which 
combines the percentage of staining (0-3) with the 
intensity score (0-3) of 56 prostate cancer patients. 
Analysis of CK2-specific NCoR phosphorylation in 
prostate cancer patients revealed that 89% of samples 
(55 tissues) show positive staining for NCoR Ser (P)-
2436, with 31% demonstrating a high score (≥5) for 
NCoR phosphorylation, 68.8% showing a high Gleason 
score (≥8), and 15.4% displaying a low Gleason score 
(≤7; Fig. 5B). High score of NCoR phosphorylation (≥5) 
was primarily observed in Gleason scores ≥8 (68.75%) 
than with Gleason scores ≤7 (15.38%), whereas the 
high score (≥5) of IP-10 was observed more often with 
Gleason scores ≤7 (33.3%) than with Gleason scores 
≥8 (12.5%), providing the inverse relationship between 
NCoR phosphorylation and IP-10 in the late stage of 
prostate cancer development (Fig. 5C). As expected, 
the survival rate of high-Gleason score (≥8) patients 
was significantly lower than that of low-Gleason score 
(≤7) patients according to Kaplan–Meier survival curve 
analyses (Fig. 5D). Notably, univariate analysis indicated 
that expression of CK2-dependent NCoR phosphorylation 
significantly correlate with a decreased survival rate (Fig. 
5E, upper panel). After stratification of the patients by 
Gleason score (≤7 and ≥8), the survival curves of patient 
with low Gleason score (≤7) were significantly different 
among NCoR phosphorylation status, but not in high 
Gleason score (≥8) group (Supplementary Figure 4). In 
the Cox proportional hazard model after adjustments for 
age and Gleason score (continuous variable), the risk of 
death was significantly increased in patients with high 
NCoR phosphorylation (hazard ratio, 6.35; p=0.03) 
compared with patients with low NCoR phosphorylation. 
evidence for the pathological relevance of CK2-
dependent NCoR phosphorylation in prostate cancer 
development. Collectively, these results demonstrate 
that IP-10 levels inversely correlate with CK2-dependent 
NCoR phosphorylation levels during prostate cancer 
development.
DISCUSSION
Discovering the molecular basis related to 
androgen-independent and hormone refractory prostate 
cancer progression is a central issue in the prostate tumor 
biology [32, 33]. Several molecular pathways, including 
AKK, MAPK, and NF-kB, have been suggested to 
explain hormone refractory prostate cancer survival and 
development [34]. In addition, the functional role of the 
AR coactivator and SRC/p160 protein complexes are 
well established and implicated in enhanced AR action 
after hormone deprivation therapy [35]. However, little 
is known about the roles of the corepressors NCoR 
and SMRT in androgen-independent prostate cancer 
development. In this study, we suggest a possible 
molecular mechanism by which NCoR modulates the 
invasive growth of androgen independent prostate 
cancer cells in a CK2-dependent manner. CK2 is known 
to participate in diverse cell signaling and aberrant 
expression of CK2 is believed to cause tumor development 
[36]. Thus, this kinase is considered a potential target 
for anti-cancer therapies. Here, we found constitutively 
elevated CK2 activity in androgen-independent DU145 
and PC-3 cells, consistent with previous reports [19, 20]. 
We also found the pattern of NCoR phosphorylation and 
stability correlates with CK2 activity in prostate cancer 
cells. Our finding is consistent with a previous report 
that the NCoR1 protein is highly elevated in androgen-
independent prostate cancer cell lines PC-3 and DU145 
when compared with LNCaP and RWPE1 cells [29]. That 
study found NCoR1 to have diagnostic and prognostic 
significance in prostate tumor samples via antagonizing 
PPARα/γ signaling. On the other hand, we could not 
observe the significant increase of NCoR and NCoR 
phosphorylation in LNCaP-derivative C4-2B cells when 
compare to both DU145 and PC-3 cells, suggesting that 
NCoR phosphorylation by CK2 may be directly relevant 
to malignancy of prostate cancer cells rather that hormone 
independency. Further work should be performed to 
unravel this discrepancy among androgen-independent 
prostate cancer cells.
In a previous study, we determined that the CK2-
NCoR cascade selectively represses the transcription of 
IP-10, which ultimately suppresses the invasion activity 
of esophageal cancer cells [18]. Here, we examined 
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the relationship between IP-10 mRNA levels and CK2-
mediated NCoR phosphorylation in PC-3 cells. Our 
results again displayed a reduced level of IP-10 in these 
cells with a concomitant elevation in CK2 activity similar 
to esophageal cancer cells. The varying levels of IP-
10 among prostate cancer cell lines was explained by 
enhanced recruitment of the NCoR-HDAC3 corepressor 
complex to the AP-1 site of the IP-10 promoter in PC-3 
cells compared with RWPE1 and LNCaP cells, which was 
reversed by blocking CK2 activity. In addition, inhibition 
of CK2 using TBB induced derepression of IP-10 and 
suppressed the invasive growth of PC-3 cells. Importantly, 
the transcriptional repression of IP-10 was selectively 
regulated by NCoR since knocking down NCoR had no 
effect on E-cadherin mRNA levels. Finally, ChIP analyses 
clearly demonstrated that the c-Jun-NCoR complex 
represses IP-10 transcription via histone deacetylation by 
HDAC3. Taken together, these results demonstrate the 
functional engagement of the NCoR-HDAC3 corepressor 
complex in regulating the invasion activity of PC-3 cells 
in a CK2-dependent manner.
Activation of EGFR signaling is also known to 
inhibit IP-10-mediated tumor cell migration [37, 38]. In 
addition, it has been recently shown that EGFR signaling 
phosphorylates and enhances the activity of CK2, thereby 
promoting tumor cell invasion [39]. Intriguingly, elevated 
expression of EGFR was recently reported to promote 
the tumorigenic growth of PC-3 cells [40]. Thus, it is 
possible that EGFR signaling enhances CK2-dependent 
NCoR phosphorylation and subsequently leads to the 
downregulation of IP-10 expression. Consistent with this 
hypothesis, we found that blocking EGFR signaling in 
PC-3 cells by ceteuximab treatment efficiently reversed the 
transcriptional repression of IP-10 as well as the stability 
and phosphorylation of NCoR (data not shown). However, 
we failed to observe the additional effect of EGF treatment 
on the level of IP-10 mRNA, which is likely due to the 
constitutive repression of IP-10 transcription in PC-3 cells. 
Therefore, CK2-mediated tumorigenic pathways may be 
controlled by extracellular receptor signaling; however, 
future studies are needed to address this issue.  
Tumor xenograft assays in mice confirmed 
that inhibition of the CK2-NCoR signaling network 
suppresses the in vivo tumorigenecity of PC-3 cells with 
derepression of IP-10 expression observed. Furthermore, 
clinicopathological analyses clearly showed the increase 
of CK2-dependent NCoR phosphorylation is inversely 
associated with the survival probability of prostate 
cancer patients, confirming our hypothesis that NCoR 
promotes oncogenesis of prostate cancer in a CK2-
dependent manner. In our study, we did not find an effect 
of NCoR phosphorylation on survival probability in 
patients with high Gleason scores. Among 16 patients 
with Gleason scores ≥8, however, most had high NCoR 
phosphorylation, and only two and three, respectively, had 
with low and moderate NCoR phosphorylation. Thus, due 
to the limitations of the small sample size in each NCoR 
phosphorylation group, we did not find a significant 
effect of NCoR phosphorylation on survival probability 
in patients with high NCoR phosphorylation. Further 
investigation with larger sample sizes will be necessary to 
confirm our results.
In summary, this study demonstrates that CK2 
promotes tumorigenic growth of androgen-independent 
prostate cancer cells via NCoR-dependent repression of 
IP-10 pathway. Therefore, our study provide the rationale 
for androgen-independent prostate cancer therapy by 
disruption of CK2-NCoR signaling network.
MATERIALS AND METHODS
Cell Culture, plasmids, and antibodies
Both human PC-3 and LNCaP were from the 
American type culture collection (ATCC) (Rockville, 
Maryland, USA) and cultured in RPMI 1640 media 
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% 
FBS. The CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole 
(TBB) was prepared as a 50 mM stock solution in DMSO 
(Sigma-Aldrich, St. Louis, MO, USA). The RWPE1 cells 
were grown in keratinocyte serum-free medium (K-SFM) 
containing 50 µg/ml bovine pituitary extract and 5 ng/ml 
epidermal growth factor. The Control cultures received 
the same amount of DMSO as experimental cultures 
and final DMSO concentrations did not exceed 0.1%. 
Transient transfections were performed using Polyexpress 
(Excellgen, Rockville, MD, USA). The following 
antibodies were used: anti-CK2 (Millipore, Billerica, MA, 
USA), anti-HA (Sigma-Aldrich and Covance, Princeton, 
NJ, USA), anti-FLAG (Sigma-Aldrich), anti-β-actin 
(Sigma-Aldrich), anti-GAPDH (Millipore), anti-NCoR 
(ATGEN, Seongnam, Gyeonggido, Korea), anti-p300 
(Millipore), anti-c-Jun (Epitomics, Burlingame, CA, 
USA), anti-c-Fos (Epitomics), anti-acetyl-histone H3 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
IP-10 (Santa Cruz Biotechnology), anti-HDAC3 (Santa 
Cruz Biotechnology), anti-SMRT (Millipore), and anti-
Myc (Cell Signaling, Danvers, MA, USA). The phospho-
NCoR antibody was described previously [18]. The 
CK2α construct was generated by PCR and cloned into 
the pSG5-KF2M1 and pSG5-KM2M1 (Sigma-Aldrich) 
plasmid vectors. Full-length pCMV-GFP-NCoR (1-2453) 
was previously described [41].
siRNA and lentiviral shRNAs
The siRNAs against NCoR and CK2α as well as 
a non-specific siRNA were obtained from GenePharma 
(Shanghai, China). For siRNA transfection, PC-3 cells 
were incubated in serum and antibiotic free RPMI 1640 
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for 12 h and 200 nM nonspecific siRNA, siRNA-NCoR, 
and siRNA-CK2 were transfected using Lipofectamine 
2000 following the manufacturer’s protocol (Invitrogen). 
After 4 h, the media was changed and cells were 
incubated for 2 days. siRNAs against NCoR and 
CK2α were designed as follows: siNCoR forward (F): 
5′-GGUGAUAAUACCAAAGAAATT-3′; reverse (R): 
5′-UUUCUUUGGUAUUAUCACCTT-3′ and siCK2α 
(F): 5′-CAGAAAGCUACGACUAAUATT-3′; (R): 
5′-UAUUAGUCGUAGCUUUCUGTG-3′. 
We established a stable PC-3 cell line with reduced 
NCoR expression using NCoR-specific shRNAs. To 
silence NCoR expression, two pairs of oligonucleotides 
coding for NCoR-specific shRNA were purchased as 
MISSION shRNAs (Sigma-Aldrich). Next, we prepared 
lentiviral particles using pLKO.1-PURO NCoR shRNA 
with a three-plasmid co-transfection following instructions 
from Invitrogen. PC-3 cells were then transfected with 
lentivirus. After 2 day incubation, lentivirus from the 
culture media was collected and concentrated with 
Centricon-plus-20 filters (Millipore). Lentivirus PURO 
shRNA was generated as a control.
Real-time PCR analyses 
Total RNA was isolated using the RNA Easyspin 
kit according to the manufacturer’s instructions (Intron, 
Korea). Total RNA from each sample was reverse 
transcribed with random primers using a StrataScript™ 
reverse transcriptase kit (Stratagene), according to 
the manufacturer’s protocol. RT–PCR analysis and 
quantification were performed with SYBR Green PCR 
Master Mix reagents (Applied Biosystems, Foster City, 
CA, USA) on an ABI Prism 7300 Sequence Detection 
System (Applied Biosystems). The specificity of the 
amplifications were verified using the Dissociation 
Analysis Software. All samples were normalized to human 
GAPDH. The primer sequences used for amplification 
of IP-10 were (F) 5′-CTGCCATTCTGATTTGCTGC-3′ 
and (R) 5′-GATGGCCTTCGATTCTGGAT-3′. Primer 
sequences for amplification of E-cadherin RNA were 
5′-AACGCATTGCCACATACATACACT-3′ (F) and 
5′-CCATGACAGACCCCTTAAAGA-3′ (R). All 
reactions were performed in triplicate. Relative expression 
levels and standard deviations were calculated using the 
comparative method. 
In vitro kinase assay
GST-fusion proteins were incubated with 500 U of 
recombinant CK2α (ATGEN) in the presence of kinase 
reaction buffer (10 µl 5× kinase buffer, 10 µl magnesium/
ATP cocktail solution 90 µl 75 mM MgCl2/500 mM 
ATP plus 10 µl [100 µCi] of [γ-32P]-ATP [3000 Ci/
mmole]) in a total volume of 50 µl for 30 min at 30°C. 
Reactions were terminated by washing twice with 1× 
kinase buffer. Samples were resuspended in 15 µl 5× 
SDS sample loading buffer and boiled for 5 min. After 
electrophoresis, SDS polyacrylamide gels were stained 
with Coomassie blue and dried, and the phosphorylated 
products were visualized by autoradiography or quantified 
by PhosphorImager analysis.
Clinical specimens 
All specimens derived from patients were collected 
and archived under protocols approved by the Institutional 
Review Board of Yonsei University College of Medicine 
(4-2012-0473). Informed consent was not required by 
the local ethics board as the study was considered an 
anonymous chart review. Patient data was analyzed 
anonymously. Archival prostate cancer tissues in paraffin 
blocks were retrieved from the Department of Pathology at 
Gangnam Severance Hospital, Yonsei University College 
of Medicine. Cores of 3-mm diameter paraffin embedded 
tissues were obtained and transferred to recipient blocks 
to make tissue microarray blocks using Quick-Ray® 
(UNITMA, Seoul, Korea). [42]
Immunohistochemical staining
Serial 4-µm sections were prepared from tissue 
microarray blocks derived from 55 patients with 
prostate cancer. The sections were used for hematoxylin 
and eosin (HE) staining and immunohistochemical 
evaluation of phospho-NCoR1 and IP-10 expression. 
Immunohistochemical staining was performed using 
EnVisionTM kit (DAKO, Glostrup, Denmark) according 
to the manufacturer’s recommended procedure. Phospho-
NCoR1 and IP-10 antibodies were used at a dilution of 
1:100. Two investigators independently reviewed the 
stained slides without knowledge of the clinical data. The 
intensity of immunohistochemical staining was evaluated 
as follows: expression score = percentage of staining (0; 
no staining, 1; <25 cells are positive, 2; 25-50%, 3; >50%) 
+ intensity score (0; no staining, 1; faint, 2; moderate, 3; 
strong) [43]. The expression score is categorized as low 
(0-2), moderate (3-4) and high (≥5).
Xenograft experiments
Cell suspensions (100 μl 1× PBS containing 1.5 × 
106 NCoR-depleted PC-3 cells or control PC-3 cells) were 
injected subcutaneously into the right flank of 5-week-
old athymic BALB/c nu/nu mice. Each experimental 
group included six mice. Tumor size was monitored 
closely and measured every 3 days using a caliper. Three 
weeks after injection, mice with comparable-sized tumors 
were selected for treatment with TBB. After 3 weeks of 
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TBB treatment, mice were sacrificed and tumors were 
harvested, photographed, and weighed. The volume of 
tumors was estimated according the formula: Volume = 
½ × a × b2, where (a) and (b) represented the largest and 
smallest diameters, respectively. At the termination of the 
study, tumors were harvested and weighed. Animal studies 
were performed after obtaining approval according to the 
guidelines of the Institutional Animal Care committee of 
the National Cancer Center Korea (NCC-08-034).
Chromatin immunoprecipitation assays (ChIP)
ChIP assays were performed with the indicated 
antibodies as described previously [44], but without SDS 
in all buffers. Eluted DNA was amplified with specific 
primers using the SYBR green PCR master mix (Applied 
Biosystems). Primers used in PCR were as follows: P1 
(forward (F): 5′-CCAGGCATTGTTTGAACTGC-3′; 
reverse (R): 5′-AGCAAAAGATGTCTTGCACAAA-3′). 
P2 (forward (F): 5′-GACTACCTCTCTCTAGAACT-3′; 
reverse (R): 5′-GATCTCAACACGTGGACAAA-3′). All 
reactions were normalized relative to input activity and 
are presented as the mean ± standard deviation (SD) from 
three independent experiments.
Cell Invasion Assays
In vitro cell invasiveness was determined by 
the ability of cells to transmigrate through a layer 
of extracellular matrix in Biocoat Matrigel invasion 
chambers (SPL Lifescience, Pocheon, Gyeonggido, 
Korea). Post-transfected cells (48 h) were trypsinized and 
seeded at a density of 2.0 × 104 per insert. After 24 h, non-
invading cells were removed with cotton swabs. Invading 
cells were fixed with 100% methanol and stained with 1% 
crystal violat (Sigma-Aldrich) before enumeration under 
an inverted microscope. Data are expressed as the mean ± 
SD of at least three independent experiments.
Duolink in situ proximity ligation assay (PLA) 
analysis
Duolink in situ PLA analysis was performed per the 
manufacturer’s instructions (OLink Biosciences, Uppsala, 
Sweden). In short, paraformaldehyde-fixed cells were 
washed with PBS, incubated for 15 min in 1.5% hydrogen 
peroxide, washed, and blocked with blocking solution. 
Primary rabbit antibody was applied and the cells were 
incubated with PLUS and MINUS secondary PLA probes 
against rabbit IgG only or against both rabbit and mouse 
IgG. The incubation was followed by hybridization, 
ligation, and amplification. After mounting with Duolink 
mounting medium, the samples were examined using 
an Olympus FluoView FV1000 Confocal Microscope 
(Olympus Corp., Tokyo, Japan).
Statistical Analyses
Statistical analyses were performed using 
Student’s t-tests with Bonferroni correction for multiple 
comparisons. A p-value less than 0.05 was considered 
statistically significant. Survival probability was measured 
from the time of surgery to disease progression or 
death, and analyzed using Kaplan-Meier method.  The 
log-rank test was employed to compare the NCoRS2436 
phosphorylation status and test the significance of Gleason 
score. Multivariate analysis was performed using the Cox 
proportional hazards model.
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